Jceler MV1 Tablet ER is a combination oral antidiabetic medication formulated to improve glycemic control in patients with type 2 diabetes mellitus. It contains Glimepiride 1mg, Metformin 500mg, and Voglibose 0.2mg, each contributing distinct mechanisms to regulate blood glucose levels effectively. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing fasting and postprandial blood glucose. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, promoting better glucose uptake by tissues. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the intestines, mitigating postprandial hyperglycemia. The extended-release (ER) formulation ensures a sustained therapeutic effect, improving patient compliance by reducing dosing frequency. Jceler MV1 is indicated for patients inadequately controlled on diet and exercise alone or those requiring combination therapy to achieve target glycemic levels. It should be used cautiously in patients with renal or hepatic impairment, and contraindicated in cases of diabetic ketoacidosis or severe infections. Regular monitoring of blood glucose and periodic assessment of renal function are recommended during therapy. Adverse effects may include hypoglycemia, gastrointestinal disturbances, and rarely, lactic acidosis. This combination offers a comprehensive approach to managing type 2 diabetes by targeting multiple pathophysiological defects.